GlycoMimetics has developed a proprietary, small molecular weight compound known as GMI-1051 for the treatment or prevention of infections caused by Pseudomonas aeruginosa, a bacterium responsible for an increasing number of infections which are frequently refractory to treatment with antibiotics.
GMI-1051 is an example of an exciting new approach to treating infectious disease, based upon an understanding of the involvement of carbohydrates in establishing and maintaining certain infections. Combination therapies are increasingly being used clinically in chronic infections. Using a glycomimetic approach to inhibit bacterial virulence factors represents a promising potential addition to the anti-infective repertoire. We believe that the compound will be used in combination with antibiotic therapy in patients who are chronically infected or in patients for whom antibiotic therapy alone is not effective.
About Pseudomonas aeruginosa
P. aeruginosa is an opportunistic pathogen that once stimulated, begins to express virulence factors and toxins. GMI-1051 inhibited the functions of both PA-IL and PA-IIL lectins in both in vitro and in vivo preclinical tests. GMI-1051 strongly inhibits the functions of both PA-IL and PA-IIL lectins in a wide range of in vitro and in vivo preclinical tests.
As demonstrated by GlycoMimetics’ ability to rationally design a single potent inhibitor of both of the Pseudomonas lectins, we are uniquely positioned to develop inhibitors against other pathogens as well.
- Read more about our Pipeline & Other Programs.